Reboxetine mesylate is used for the treatment of DSM-III-R-defined panic disorder by significantly reducing the frequency of panic attacks and associated symptoms; it is also used in the treatment of recurrent DSM-III-R-defined major depressive disorder, where it significantly reduces relapse rates compared to placebo (22% vs. 56%) and maintains a higher cumulative probability of sustained response; additionally, it effectively prevents relapse of depressive symptoms; reboxetine is further applied in the reduction of nicotine self-administration in a dose-dependent manner, showing potential utility in smoking cessation therapy.